0714 GMT - Novartis's quarterly results exceeded expectations once again, but this might be overshadowed by news of the retirement of its well-regarded financial chief and concerns about psoriasis drug Cosentyx, Intro Health's Naresh Chouhan and Dominic Rose say. "Harry Kirsch, who is widely considered the best CFO in the industry by investors, is to retire," the analysts write in a research note. Moreover, Cosentyx sales missed expectations and only grew 6% at constant currency, the analysts say. The company called out rising competition in the U.S., slower growth elsewhere and price cuts in the Chinese market, but remains confident in a peak annual sales target of $8 billion, the analysts say. Shares fall 2.6%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

July 17, 2025 03:14 ET (07:14 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.